Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Hugeltox Inj. in Essential Blepharospasm
Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Hugeltox Inj. In Essential Blepharospasm Running Parallel With Phase I Study
Sponsor: Hugel
Listed as NCT01791881, this PHASE3 trial focuses on Essential Blepharospasm and remains completed. Sponsored by Hugel, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE3
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hugel
For direct contact, visit the study record on ClinicalTrials.gov .